European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
暂无分享,去创建一个
Francisco Cervantes | Simona Soverini | Giovanni Martinelli | Giuseppe Saglio | Philippe Rousselot | Martin C. Müller | Andreas Hochhaus | Martin C Müller | Fabrizio Pane | Bengt Simonsson | Rüdiger Hehlmann | J. Radich | R. Larson | M. Baccarani | R. Clark | H. Kantarjian | G. Rosti | G. Martinelli | J. Cortes | M. Deininger | J. Lipton | D. Niederwieser | J. Goldman | R. Silver | G. Saglio | P. Rousselot | F. Mahon | S. Soverini | F. Pane | R. Hehlmann | A. Hochhaus | C. Schiffer | F. Guilhot | Dong-Wook Kim | T. Hughes | H. Hjorth-Hansen | F. Cervantes | J. Apperley | Jiri Mayer | Michele Baccarani | Timothy P Hughes | B. Simonsson | Hagop M Kantarjian | Jeffrey H Lipton | François-Xavier Mahon | Richard A Larson | François Guilhot | Jorge E Cortes | John M Goldman | Henrik Hjorth-Hansen | Dong-Wook Kim | Jerald P Radich | Michael W Deininger | J. Mayer | Richard E Clark | Gianantonio Rosti | Dietger Niederwieser | Jane F Apperley | S. Saussele | J. Steegmann | Susanne Saußele | Charles Schiffer | Richard Silver | Juan-Luis Steegmann | T. Hughes
[1] H. Kantarjian,et al. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. , 2009, Blood.
[2] A. Mócsai,et al. Dasatinib inhibits proinflammatory functions of mature human neutrophils , 2012, Blood.
[3] M. Deininger,et al. Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR–ABL inhibitors as first-line therapy , 2012, Leukemia.
[4] K. Travers,et al. Single Molecule Real Time (SMRT™) Sequencing Sensitively Detects the Evolution of Polyclonal and Compound BCR-ABL Mutations in Patients Who Relapse On Kinase Inhibitor Therapy , 2012 .
[5] H. Kantarjian,et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T 315 I mutation , 2012 .
[6] H. Kantarjian,et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. , 2011, Blood.
[7] J. Apperley. Part II: management of resistance to imatinib in chronic myeloid leukaemia. , 2007, The Lancet. Oncology.
[8] M. Baccarani,et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. , 2009, Blood.
[9] H. Kantarjian,et al. Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. , 2009, Blood.
[10] Martin C. Müller,et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). , 2010, Blood.
[11] M. Baccarani,et al. Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. , 2012, Blood.
[12] Brian Walters,et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate , 2006, Nature Medicine.
[13] J. Radich,et al. Chronic myelogenous leukemia. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.
[14] T. Brümmendorf,et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. , 2011, Blood.
[15] I. Flinn,et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. , 2011, The Lancet. Oncology.
[16] P. Valent. Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities , 2011, Haematologica.
[17] R. Larson,et al. Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase , 2011, European Journal of Clinical Pharmacology.
[18] L. Staudt,et al. Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients. , 2012, Blood.
[19] H. Scott,et al. Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] B. Dörken,et al. Severe peripheral arterial disease during nilotinib therapy. , 2011, Journal of the National Cancer Institute.
[21] Martin C. Müller,et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. , 2010, Blood.
[22] M. Baccarani,et al. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome‐negative cells , 2007, Cancer.
[23] R. Engh,et al. Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients , 2012, Leukemia.
[24] H. Kantarjian,et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. , 2003, Blood.
[25] H. Kantarjian,et al. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. , 2009, Blood.
[26] T. Brümmendorf,et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Susan Branford,et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Simona Soverini,et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. , 2011, Blood.
[29] Martin C. Müller,et al. ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia , 2008, Haematologica.
[30] Martin C. Müller,et al. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. , 2011, Blood.
[31] J. Radich,et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study , 2013, Leukemia.
[32] M. Baccarani,et al. Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. , 2011, Blood.
[33] M. Baccarani,et al. Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] M. Baccarani,et al. Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. , 2013, Blood.
[35] Claude Preudhomme,et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. , 2010, The New England journal of medicine.
[36] M. Gordon. Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia , 2010 .
[37] H. Kantarjian,et al. Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia , 2011, Cancer.
[38] P. Valent,et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML , 2011, American journal of hematology.
[39] Ya-Zhen Qin,et al. Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. , 2011, Blood.
[40] Susan Branford,et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. , 2003, The New England journal of medicine.
[41] J. Radich,et al. International randomized study of interferon Vs STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib , 2009 .
[42] Martin C. Müller,et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. , 2008, Blood.
[43] J. Mestan,et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. , 2005, Cancer research.
[44] H. Kantarjian,et al. Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure–response analysis of a Phase III study , 2013, Clinical pharmacology : advances and applications.
[45] H. Kantarjian,et al. Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] M. Krajinovic,et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. , 2008, Blood.
[47] Martin C. Müller,et al. A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial , 2012 .
[48] N. Cross,et al. Standardized definitions of molecular response in chronic myeloid leukemia , 2012, Leukemia.
[49] Rocco Piazza,et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] J. Radich,et al. Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib , 2012, Haematologica.
[51] H. Kantarjian,et al. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. , 2011, Blood.
[52] M. Baccarani,et al. Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. , 2012, Blood.
[53] Z. Estrov,et al. Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy , 2010, Cancer.
[54] R. Larson,et al. Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Based On Early Molecular Response and Factors Associated with Early Response: 4-Year Follow-up Data From Enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients) , 2012 .
[55] J. Burke,et al. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] Suzanne Kamel-Reid,et al. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. , 2012, Blood.
[57] J. Goldman. How I treat chronic myeloid leukemia in the imatinib era. , 2007, Blood.
[58] M. Baccarani,et al. Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML. , 2012, Cancer treatment reviews.
[59] K. Rezvani,et al. Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. , 2013, Blood.
[60] A. Racine‐Poon,et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] Martin C. Müller,et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. , 2011, Blood.
[62] R. Arceci. Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile , 2012 .
[63] R. Larson,et al. Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase , 2012, Leukemia.
[64] A. Vekhoff,et al. Relationship Between Molecular Responses and Disease Progression in Patients (Pts) Treated First Line with Imatinib (Im) Based Regimens: Impact of Treatment Arm within the French Spirit Trial From the French CML Group (FI LMC) , 2012 .
[65] J. Hasford,et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. , 1998, Journal of the National Cancer Institute.
[66] M. Baccarani,et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). , 2012, Blood.
[67] Francisco Cervantes,et al. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. , 2013, Blood.
[68] B. Dörken,et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib , 2013, Leukemia.
[69] Sukjoong Oh,et al. Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors , 2014, Haematologica.
[70] M. Baccarani,et al. Monitoring treatment of chronic myeloid leukemia , 2008, Haematologica.
[71] M. Nöthen,et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer , 2012, Nature Medicine.
[72] K. Vandyke,et al. Dysregulation of bone remodeling by imatinib mesylate. , 2010, Blood.
[73] L. Staudt,et al. Clinical Trials and Observations , 2007 .
[74] R. Hehlmann,et al. Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia , 2011, Leukemia.
[75] J. Melo,et al. In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. , 2010, Blood.
[76] Stefan W Krause,et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[77] S. Corey,et al. How I treat childhood CML. , 2012, Blood.
[78] Susan O'Brien,et al. Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate , 2005, Clinical Cancer Research.
[79] F. Gherlinzoni,et al. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. , 2011, Blood.
[80] Dong-Wook Kim,et al. The long-term clinical implications of clonal chromosomal abnormalities in newly diagnosed chronic phase chronic myeloid leukemia patients treated with imatinib mesylate. , 2012, Cancer genetics.
[81] J. Melo,et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR , 2010, Leukemia.
[82] R. Hehlmann. How I treat CML blast crisis. , 2012, Blood.
[83] Philippe Rousselot,et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. , 2010, The Lancet. Oncology.
[84] M. Baccarani,et al. Chronic myeloid leukaemia , 2007, The Lancet.
[85] H. Kantarjian,et al. The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure. , 2013, Clinical lymphoma, myeloma & leukemia.
[86] Martin C. Müller,et al. Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[87] M. Baccarani,et al. Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure , 2009, Haematologica.
[88] C. Carcassi,et al. Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. , 2009, Blood.
[89] Francisco Cervantes,et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.
[90] Martin C. Müller,et al. Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial , 2012 .
[91] H. Kantarjian,et al. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy , 2012, Cancer.
[92] M. Iacono,et al. Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. , 2013, Blood.
[93] L. Dušek,et al. Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000 – a report from the population‐based CAMELIA Registry , 2011, European Journal of Haematology.
[94] J. Goldman,et al. Three decades of transplantation for chronic myeloid leukemia: what have we learned? , 2011, Blood.
[95] J. Radich,et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia , 2010, Leukemia.
[96] J. Cayuela,et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. , 2005, Blood.
[97] R. Arceci,et al. A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib , 2010 .
[98] Francisco Cervantes,et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. , 2006, Blood.
[99] T. Brümmendorf,et al. Assessment of Early Molecular Response As a Predictor of Long-Term Clinical Outcomes in the Phase 3 BELA Study , 2012 .
[100] Dong-Wook Kim,et al. Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation , 2012, International Journal of Hematology.
[101] H. Kantarjian,et al. Six-year (yr) follow-up of patients (pts) with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib. , 2011 .
[102] M. Deininger,et al. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia , 2011, Leukemia.
[103] P. Manley,et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[104] M. Talpaz,et al. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia , 2011, Leukemia.
[105] R. Tuma,et al. Signaling through cannabinoid receptor 2 suppresses murine dendritic cell migration by inhibiting matrix metalloproteinase 9 expression. , 2012, Blood.
[106] G. Canellos,et al. Chronic granulocytic leukemia. , 1976, The Medical clinics of North America.
[107] D. Colomer,et al. Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group , 2010, Haematologica.
[108] Francisco Cervantes,et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.
[109] J. Radich,et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. , 2011, Blood.
[110] Martin C. Müller,et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib , 2010, Haematologica.
[111] M. Gordon. Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia , 2010 .
[112] B. Dörken,et al. Clinical cardiac safety profile of nilotinib , 2012, Haematologica.
[113] Martin C. Müller,et al. Secondary Malignancies in CML Patients – Data From the German CML Study IV , 2012 .
[114] T. Brümmendorf,et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. , 2012, Blood.
[115] C. Sawyers. Chronic myeloid leukemia. , 1999, The New England journal of medicine.
[116] H. Scott,et al. Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile. , 2012, Blood.
[117] C. Eaves,et al. Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate. , 2010, Blood.
[118] Andreas Hochhaus,et al. Chronic myeloid leukaemia , 2007, The Lancet.
[119] R. Larson,et al. Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance , 2013, Leukemia.
[120] A. Bennaceur-Griscelli,et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. , 2011, Blood.
[121] R. Larson,et al. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy , 2010, Leukemia.
[122] A. Zarbock. The shady side of dasatinib. , 2012, Blood.
[123] R. Larson,et al. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. , 2013, Blood.
[124] P. Szankasi,et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. , 2013, Blood.
[125] F. Gherlinzoni,et al. Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study , 2012, British Journal of Cancer.
[126] M. Höglund,et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[127] K. Rezvani,et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. , 2008, Blood.
[128] Arnon Nagler,et al. Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. , 2011, Blood.
[129] Jaspal Kaeda,et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[130] I. Flinn,et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. , 2012, The New England journal of medicine.
[131] G. Specchia,et al. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib , 2013, Leukemia.
[132] I. Flinn,et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up , 2012, Leukemia.
[133] H. Kantarjian,et al. Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. , 2011, Blood.
[134] D. Marin,et al. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. , 2011, Leukemia research.
[135] R. Clark,et al. Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. , 2012, Blood.
[136] Katayoun Rezvani,et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[137] Simona Soverini,et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. , 2006, Blood.
[138] M. Gordon. Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial , 2010 .
[139] F. Giles,et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis , 2013, Leukemia.
[140] D. Mould,et al. Pharmacokinetic–pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia , 2013, Cancer Chemotherapy and Pharmacology.
[141] M. Baccarani,et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. , 2011, Blood.
[142] T. Clackson,et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. , 2009, Cancer cell.
[143] J. Cortes,et al. Re-emergence of interferon-α in the treatment of chronic myeloid leukemia , 2012, Leukemia.
[144] J. Radich,et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[145] J. Hasford,et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. , 2011, Blood.
[146] N. Cross,et al. Harmonization of molecular monitoring of CML therapy in Europe , 2009, Leukemia.
[147] C. Baldwin,et al. Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN‐AML) and FLT3ITD , 2011, American journal of hematology.
[148] J. Radich,et al. Chronic myelogenous leukemia, version 1.2014: Featured updates to the NCCN guidelines , 2013 .
[149] K. Porkka,et al. Off-target effects of BCR–ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia , 2012, Leukemia & lymphoma.
[150] J. Radich,et al. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy , 2013, Haematologica.
[151] Giovanni Martinelli,et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. , 2009, Blood.
[152] H. Kantarjian,et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. , 2012, Blood.
[153] Francisco Cervantes,et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia , 1984 .
[154] R. Bhatia,et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. , 2011, Blood.
[155] H. Kantarjian,et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic‐phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors , 2013, American journal of hematology.
[156] D. Marin,et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[157] R. Foà,et al. Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty , 2013, Haematologica.
[158] H. Kantarjian,et al. Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy , 2012, Haematologica.
[159] T. Brümmendorf,et al. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase , 2008, Leukemia.
[160] D. Marin,et al. Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia , 2010, Haematologica.
[161] L. Vidal,et al. Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis , 2013, Haematologica.
[162] H. Kantarjian,et al. Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data , 2012 .
[163] Sukjoong Oh,et al. Efficacy and Safety of Radotinib in Chronic Phase Chronic Myeloid Leukemia Patients with Resistance or Intolerance to BCR-ABL Tyrosine Kinase Inhibitors: Radotinib Phase 2 Clinical Trial , 2012 .
[164] J Hermans,et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation , 1998, The Lancet.
[165] A. Baruchel,et al. The International Registry for Chronic Myeloid Leukemia (CML) in Children and Adolescents (I-CML-Ped-Study): Objectives and Preliminary Results , 2012 .
[166] Martin C. Müller,et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. , 2008, Blood.
[167] M. Baccarani,et al. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results , 2012, Leukemia.
[168] H. Einsele,et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML) , 2012, Leukemia.
[169] H. Kohrt,et al. Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. , 2012, Blood.
[170] N. Shinton. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 2007 .
[171] H. Kantarjian,et al. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. , 2008, Blood.
[172] Deborah L White,et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. , 2008, Blood.
[173] J. Apperley. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. , 2007, The Lancet. Oncology.